# Anergis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/anergis

- Industry: Biotechnology
- Headquarters: Switzerland
- Website: www.anergis.ch
- Total disclosed funding: $35M
- Latest round: Series B (Dec 3, 2014)
- Investors on record: 5

## About

Anergis SA is a biotechnology company based in Switzerland, specializing in the development and manufacturing of innovative allergy immunotherapy products aimed at effectively alleviating allergy symptoms for patients.Founded in 2001, Anergis SA operates in the biotechnology sector, focusing on allergy immunotherapy. The company has completed 4 deals, with its most recent deal on April 4, 2016, raising CHF 5 million from existing investors. Anergis is headquartered in Switzerland and is known for its specialized allergy treatment solutions.Anergis.ch specializes in innovative solutions within the biotechnology sector, focusing primarily on the development and manufacturing of allergy immunotherapy products. Their core offerings revolve around advanced immunotherapy treatments designed to desensitize patients to specific allergens, effectively alleviating allergy symptoms and enhancing quality of life. These products are typically intended for individuals suffering from common allergens, which can range from pollen to pet dander, and cater to a diverse client base that includes healthcare providers, allergists, and patients across several geographical markets in Europe and North America. The company's products aim to address the rising prevalence of allergic conditions and provide efficient therapeutic alternatives, promoting patient compliance through their user-friendly administration methods. Since their introduction, these products have undergone rigorous clinical trials to ensure safety and efficacy, positioning Anergis.ch as a credible player in the allergy treatment market.Anergis.ch generates revenue primarily through a B2B model, engaging directly with healthcare institutions and practitioners who utilize their allergy immunotherapy products. The transaction structure is characterized by bulk purchasing agreements and potential subscription models for ongoing product supply and support services. Their flagship products are priced competitively within the allergy treatment market, reflecting their efficacy and the value they provide to healthcare providers and patients alike. Revenue is derived from both one-time sales and recurring orders, as healthcare providers restock their inventories based on patient needs and treatment regimens. By maintaining strong relationships with healthcare practitioners, Anergis.ch ensures a steady flow of transactions that contribute to its overall revenue stream.In April 2016, Anergis raised CHF 5 million in additional venture funding to support its upcoming product development initiatives. The company aims to expand its product line of allergy immunotherapy products, targeting a launch within the next 18 months. Anergis is also exploring expansion into new markets in North America and parts of Asia by the end of 2024, leveraging its recent funding to enhance research and development efforts and establish strategic partnerships.

## Funding rounds

- Series B, Dec 3, 2014, $15M — BioMed Partners, Renaissance Foundation & Management, Heartcore Capital, Initiative Capital Romandie, Esperante Ventures
- Series A, Mar 28, 2011, $20M — BioMed Partners, Renaissance Foundation & Management, Heartcore Capital, Initiative Capital Romandie, Esperante Ventures

## Investors

- BioMed Partners (https://capitalatlas.ai/funds/biomed-partners) — Series A, Series B
- Renaissance Foundation & Management (https://capitalatlas.ai/funds/renaissance-foundation-management) — Series A, Series B
- Heartcore Capital (https://capitalatlas.ai/funds/heartcore-capital) — Series A, Series B
- Initiative Capital Romandie — Series A, Series B
- Esperante Ventures (https://capitalatlas.ai/funds/esperante-ventures) — Series A, Series B